GAITHERSBURG, Md., June 05, 2017 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ:OPGN) today announced the results from additional studies supporting the capabilities of its Acuitas Rapid Test and Acuitas Whole Genome Sequence Analysis to accurately predict antibiotic resistance and for infection control. The results of these studies were presented in poster presentations at ASM Microbe 2017 in New Orleans, LA.
The first poster, titled “Predicting Antibiotic Resistance in Gram-Negative Bacilli by Rapid Detection of Resistance Genes,” builds upon data presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on the accuracy of the company’s molecular antibiotic susceptibility tests (AST) for predicting resistance. Having compared PCR results for 126 families of resistance genes with phenotypic AST across 1,968 E. coli and 1,499 K. pneumoniae clinical isolates, these data demonstrated a 67-96% accuracy range for predicting resistance to 25 antibiotics.
The second poster, titled “Core Genome Multilocus Sequence Typing Scheme for High-Resolution Typing of Escherichia coli,” leveraged the capabilities of the Acuitas Whole Genome Sequence Analysis to generate a high-resolution Core Genome Multilocus Sequencing Typing Scheme (cgMLST) for 2,300 gene targets. These data demonstrated the utility of the Acuitas Whole Genome Sequence Analysis to validate a stable and high-resolution strain-typing schema to be utilized for investigating the transmission and preventing the spread of multidrug-resistant microorganisms.
“These data presented at ASM Microbe 2017 further demonstrate the potential of our Acuitas products and the Acuitas Lighthouse Knowledgebase,” said Evan Jones, Chairman and CEO of OpGen. “The data from our development work continue to improve and mature as we move closer to commercialization.”
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
OpGen, Acuitas, Acuitas Lighthouse and QuickFISH are registered trademarks of OpGen, Inc.
Forward-Looking Statements
This press release includes statements relating to the company’s products and services development efforts. These statements and other statements regarding our future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek regulatory approval for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen’s business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACT: OpGen Contact: Michael Farmer Director, Marketing 240-813-1284 mfarmer@opgen.com InvestorRelations@opgen.com Investor and Media Contact: Cammy Duong MacDougall Biomedical Communications 781-591-3443 cduong@macbiocom.com
